The strategic agreement combines the capacity and capabilities of OBiO process development (PD) scientists with enabling platforms and support from Univercells Technologies. The combined know-how and capabilities will put OBiO in the best position to offer best-in-class GMP manufacturing services from R&D to commercial stages to gene therapy developers. 

“Bringing gene therapies to market safely requires reliable, scalable manufacturing technologies. We were intrigued by the potential and became early adopters of the scale-X technology in 2020. Our recently published poster details the successful scale-up of an oncolytic Herpes Simplex Virus Type-1 (HSV-1) vector from scale-X hydro (2.4 m²) to scale-X carbo bioreactor (30 m²), with  significant reductions in manpower, materials and space requirements,” said Jia Guodong, CEO, OBiO. “We will pursue this comprehensive collaboration with Univercells Technologies in multi products, conducting process development in the advanced fixed-bed bioreactor not only for HSV, but also for Lentiviral vector, Adeno-associated virus and other cell and gene therapy modalities. Such holistic capability will help customers accelerate their cell and gene therapy development while bringing substantial time and cost-saving benefits to developers and patients.”

“As we enter this agreement, the teams are already planning to scale up the oncolytic HSV-1 process in the 600m² scale-X nitro integrated in the continuous NevoLine Upstream platform in record time. The work has been rewarding because both companies share a joint mission of applying technology innovation to enable gene therapies for better lives,” said Florence Vicaire, CCO, Univercells Technologies. “Throughout the process, OBiO has been an exceptional partner, demonstrating deep expertise in advancing gene therapy candidates from bench to clinics. We look forward to further increasing their capabilities to meet the growing demand for gene therapies at a reduced cost, in China and globally.”